On Monday, Anthera Pharmaceuticals Inc (NASDAQ:ANTH)’s shares inclined 11.63% to $8.64.
Anthera Pharmaceuticals Inc (ANTH) was a big mover last session, as its shares rose almost 13% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. Yesterday’s rally continues the recent uptrend for the company, as the stock is now up nearly 73% in the past one-month time frame.
Over the last 30 days, the company witnessed two positive estimate revisions and the Zacks Consensus Estimate also moved higher, suggesting more solid trading ahead. So make sure to keep an eye on this stock going forward to see if yesterday’s jump can turn into more strength down the road.
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for patients with unmet medical needs. It is developing blisibimod, a Phase III product candidate that targets B-cell activating factor associated with various B-cell mediated autoimmune diseases, counting systemic lupus erythematosus, Immunoglobulin A nephropathy, lupus nephritis, and others.
Energy Transfer Partners LP (NYSE:ETP)’s shares gained 0.96% to $55.51.
Energy Transfer Partners LP (ETP) offered further details on its formerly declared Revolution Project that will significantly enhance its operations in the growing Marcellus and Upper Devonian production areas of Western Pennsylvania. ETP has reached long-term gas gathering, processing, and fractionation agreements with EdgeMarc Energy. To facilitate these agreements, ETP has purchased about twenty miles of high pressure pipeline from EdgeMarc and will build a new cryogenic gas processing plant, a new fractionators and additional gas gathering pipelines.
ETP plans to construct about 100 miles of high pressure 24- and 30-inch rich gas pipeline providing a total gathering system capacity in excess of 440 million cubic feet per day. The Revolution Pipeline originates in Butler County, Pennsylvania and will extend to ETP’s Revolution Plant, a new cryogenic gas processing plant to be constructed in Western Pennsylvania. The Revolution Plant is predictable to be in-service by the second quarter of 2017 and will allow for future processing growth for additional third party gas.
Energy Transfer Partners, L.P. engages in the natural gas midstream, and intrastate transportation and storage businesses in the United States. The company’s Intrastate Transportation and Storage segment transports natural gas from various natural gas producing areas, in addition to through its ET fuel system and HPL system. This segment owns and operates about 7,700 miles of natural gas transportation pipelines and three natural gas storage facilities in Texas.
At the end of Monday’s trade, Neurometrix Inc (NASDAQ:NURO)‘s shares surged 4.26% to $0.980.
Neurometrix Inc (NURO) declared the full commercial launch of Quell, which is now accessible on the Company’s product website at QuellRelief.com and at select physicians’ offices. Quell is an easy-to-use, over-the-counter chronic pain relief device. This first-of-its-kind wearable device utilizes NeuroMetrix’s patented, non-invasive nerve stimulation technology to provide 100 percent drug-free chronic pain relief. It is designed for people with painful diabetic neuropathy, sciatica, osteoarthritis and fibromyalgia, among other conditions.
Worn just below the knee, Quell calibrates automatically for every user, determining the ideal therapeutic intensity of electrical nerve stimulation to provide optimal pain relief. Quell triggers a central inhibition effect that “turns down the volume” of pain signals by stimulating the sensory nerves, which causes the brain to release endogenous opioids that ultimately reduce pain signal transmission. Quell provides widespread pain relief and is more than twice as strong as ordinary TENS devices, which typically provide only localized pain relief.
NeuroMetrix, Inc., a medical device company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders, such as those associated with carpal tunnel syndrome, lumbosacral disc disease and spinal stenosis, and diabetes.
Viacom, Inc. (NASDAQ:VIAB), ended its Monday’s trading session with -0.53% loss, and closed at $66.05.
Paramount Pictures Corporation (PPC), a global producer and distributor of filmed entertainment, is a unit of Viacom, Inc. (VIAB).
To celebrate the release of the highly anticipated film “TERMINATOR GENISYS,” Paramount Pictures, Skydance Productions, Arnold Schwarzenegger and Waze (www.waze.com) have teamed up to give drivers around the world the ultimate voice navigation machine: Arnold Schwarzenegger as the ‘Guardian’ Terminator from “TERMINATOR GENISYS.”
Starting, users of the world’s largest community-based traffic and navigation app can select custom Terminator voice commands from the Terminator himself. The Terminator will give directions to user’s destinations and alert them if a T-1000 is spotted ahead. In addition, movie theater locations showing “TERMINATOR GENISYS” will be branded with the iconic red-eyed Endoskull, assisting WAZE users to see the film when it opens in theaters on July 1st, 2015.
Viacom Inc. operates as an entertainment content company in the United States and internationally. The company creates television programs, motion pictures, short-form video, applications, games, consumer products, social media, and other entertainment content.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
